Empagliflozin
As of the edition of 20 October 2026, Empagliflozin is a small molecule: marketed, first approved in 2014 (EU); acts on SLC5A2; US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Jardiance
- First approved
- 22 May 2014 (EU)
- Approvals on record
- 36 in 6 regions
- Holder of the most recent approval
- Boehringer Ingelheim; 3 holders in all
- Registered trials
- 401, 23 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Digestive system
US protection
US protection ends in 2028.
The last listed US drug-substance patent ends in 2028. The application that gives this date is held by Boehringer Ingelheim.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product53 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 53 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Empagliflozin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC5A2 | Sodium/glucose cotransporter 2 | P31639 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 81 | 50 | 15 | 1 |
| Phase 1 | 96 | 74 | 14 | 0 |
| Phase 2 | 61 | 29 | 19 | 9 |
| Phase 3 | 79 | 40 | 20 | 5 |
| Phase 4 | 84 | 42 | 19 | 8 |
| All trials | 401 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Applicant and Lead sponsor of trials | 2007 to now |